If you have been reading about LC-MS/MS and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-08-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
=== Nobel Prize === The Nobel Committee reacted almost immediately to the first successful clinical trials. In the autumn of 1923, Banting and Macleod received the Nobel Prize in Physiology or Medicine, even though the long-term importance of the discovery was not yet apparent. They were nominated by the Danish physiologist and Nobel laureate August Krogh, who had a diabetic wife and had visited Macleod's laboratory and taken the method back to Denmark. Banting "had well-placed friends in Toronto" and "knowing that a Nobel Prize might well be awarded for insulin, they worked very hard to have Banting honoured, at home and abroad, as the discoverer of insulin". However, "among experienced scientists there was more support for the view that Banting and Best’s somewhat fumbling researches would not have reached the goal without the contributions of both Macleod and Collip". The committee judged that Macleod's work in interpreting the data, managing the clinical trials and providing a high level of public presentation were crucial for success, and "concluded that Banting would not have found the way to insulin without the guidance of Macleod", so they awarded the Nobel prize to both. Banting was furious, as he was convinced that Best should have received the other half, and he even thought of rejecting the prize. He was finally persuaded to accept it but gave half of his prize money to Best. Macleod in turn gave half of his to Collip. In 1972 the Nobel Foundation officially conceded that omitting Best was a mistake.
The division had been so rushed to get this brigade to the battlefront that it ignored individual deployment criteria. Paratroopers who had just returned from Vietnam now found themselves suddenly going back. The howl of soldier complaints was so vehement that the Department of the Army was soon forced to give each trooper who had deployed to Vietnam with the 3d Brigade the option of returning to Fort Bragg or remaining with the unit. To compensate for the abrupt departures from home for those who elected to stay with the unit, the Army authorized a month leave at the soldiers' own expense or a two-week leave with government aircraft provided for special flights back to North Carolina. Of the 3,650 paratroopers who had deployed from Fort Bragg, 2,513 elected to return to the United States at once. MACV had no paratroopers to replace them, and overnight the brigade was transformed into a separate light infantry brigade, airborne in name only.
Vatiquinone (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name, JANTooltip Japanese Accepted Name), also known as α-tocotrienol quinone or vincerenone and by its developmental code names EPI-743 and PTC-743, is a synthetic analogue of coenzyme Q10, antioxidant, and oxidoreductase inhibitor which is under development for the treatment of Friedreich's ataxia, mitochondrial disorders, epilepsy, Leigh disease, methylmalonic acidemia, noise-induced hearing loss, Parkinson's disease, Rett syndrome, and Tourette's syndrome. It is taken orally. The drug inhibits 15-lipoxygenase (15-LOX; ALOX15) and/or other oxidoreductases, enzymes involved in inflammation, ferroptosis, and oxidative stress. It has also been described as a selective 15-LOX inhibitor however. The antioxidant activities of vatiquinone are said to be 1,000- to 10,000-fold greater than those of resveratrol, idebenone, or coenzyme Q10. Mitochondrial dysfunction results in excessive production of reactive oxygen and reactive nitrogen species, which causes redox imbalance and glutathione deficiency. Vatiquinone may increase intracellular glutathione levels and thereby theoretically improve redox balance to treat mitochondrial disorders. Vatiquinone is or has been under development by Edison Pharmaceuticals and PTC Therapeutics, among other organizations.
HIV-1 protease or PR is a retroviral aspartyl protease (retropepsin), an enzyme involved with peptide bond hydrolysis in retroviruses, that is essential for the life-cycle of HIV, the retrovirus that causes AIDS. HIV-1 PR cleaves newly synthesized polyproteins (namely, Gag and Gag-Pol) at nine cleavage sites to create the mature protein components of an HIV virion, the infectious form of a virus outside of the host cell. Without effective HIV-1 PR, HIV virions remain uninfectious.
Even though slavery is illegal throughout Africa, forms of modern slavery continue to occur. The 2023 Global Slavery Index, estimated that about 7 million people in Africa were living in conditions of modern slavery, including approximately 3.8 million in forced labour and 3.2 million in forced marriage. Descent-based slavery, in which slave status is inherited, has also continued to be reported in parts of the Sahel, including Mali, Mauritania, Niger, Chad and Sudan..
Sources: en.wikipedia.org
== Etymology == The word pepper derives from Old English pipor, Latin piper, and Greek πέπερι. The Greek likely derives from Sanskrit. In the 16th century, people began using pepper to also mean the New World chilli pepper (genus Capsicum), which is not closely related.
== Expert reviews of the evidence == Letby has maintained that she is innocent of the offences for which she was convicted. Following the trials, a number of medical, statistical and other scientific experts have criticised the prosecution's evidence. The defence have been criticised for failing to call any of their own expert witnesses at trial. In 2025, a panel of experts convened by neonatologist Shoo Lee, provided with the infants' records and other trial evidence by Letby's legal representatives, published an assessment of the cases which presented alternative explanations for all of the deaths and collapses. The infants' families and the prosecution's lead expert witness have disputed these findings. The Court of Appeal has previously rejected challenges to the safety of the convictions.
== Revival of fine teas == Yellow and white teas became difficult to find in the United States and even green tea had become uncommon because of the People's Republic of China's ban on exports to the U.S. After the ban was lifted in 1971, these teas typical to China re-entered the American market for the first time since the first two decades of the 20th century. In the early 1980s, a mini-revival of demand for better quality teas from all origins occurred in the United States. Prior to this time, much of the tea available in 20th century U.S. was blended specifically for gallon and half-gallon sized iced tea bags, with the quality of not "creaming down" (a creamy looking color that imparts to some teas after cooling down) when iced as a needed aspect; "clear-liquoring" teas were required. Most iced tea blends in the U.S. have traditionally been made from the teas of Indonesia, Sri Lanka, Kenya, Argentina and Malawi. A recent rise in the demand for orthodox tea in both gallon and half-gallon iced tea bags, as well as 500 and 1,000 gram loose tea packs has caused manufacturers to reinstate orthodox manufacturing methods. This is a departure from the more common Sri Lankan, Indonesian, Argentinian and other nations' orthodox rotorvane tea-making method which has limitations and can not produce whole leaf black tea. The rotorvane method was adopted primarily to satisfy the demand for the smaller leaf sizes that fit into small (1-2 gram) tea bag blends worldwide starting in the early 20th century.}
== Food chain versus food web == A food chain differs from a food web as a food chain follows a direct linear pathway of consumption and energy transfer. Natural interconnections between food chains make a food web, which are non-linear and depict interconnecting pathways of consumption and energy transfer.
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.